PRECIGEN, INC. Accounts Receivable, Allowance for Credit Loss, Writeoff
PRECIGEN, INC. (PGEN) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $1.11 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2020-11-09
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2020-09-30 was $920.00K.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2015-12-31 was $129.00K.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2015-09-30 was $0.00.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for the quarter ending 2015-06-30 was $25.00K.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2018 was $1.27M, a 338.41% increase from fiscal 2017.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2017 was $289.00K, a 15.25% decline from fiscal 2016.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2016 was $341.00K, a 41.49% increase from fiscal 2015.
- PRECIGEN, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2015 was $241.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 3 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 6 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 9 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month |
|---|---|---|---|---|
| 2020-09-30 | $920.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $1.11M 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $190.00K 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $1.27M 10-K · filed 2019-03-01 | |||
| 2017-12-31 | $289.00K 10-K · filed 2019-03-01 | |||
| 2016-12-31 | $341.00K 10-K · filed 2019-03-01 | |||
| 2015-12-31 | $129.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $129.00K derived: sum of 2 quarters · filed 2018-03-01 | $154.00K derived: sum of 3 quarters · filed 2018-03-01 | $241.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $25.00K derived: sum of 2 quarters · filed 2015-11-09 | $112.00K 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $112.00K 10-Q · filed 2015-08-10 | ||
| 2015-03-31 | $87.00K 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |